Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies

Vincenzo di Noia, Ettore D'Argento, Sara Pilotto, Giulia Grizzi, Mario Caccese, Roberto Iacovelli, Giampaolo Tortora, Emilio Bria

Research output: Contribution to journalArticle

Abstract

Introduction: Over the last decade, epidermal growth factor receptor (EGFR) signaling was investigated as a potential target for tyrosine kinase inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Necitumumab is a fully humanized IgG1 monoclonal antibody directed against the binding domain of EGFR, approved in combination with cisplatin–gemcitabine for the first-line treatment of squamous NSCLC. Areas covered: The purpose of this manuscript is to systematically review the state of the art of necitumumab for the treatment of metastatic NSCLC, focusing on predictive factors, cost-effectiveness, and future potential combinations with additional agents. Expert opinion: Despite recent therapeutic advances, platinum-based chemotherapy still represents the most widely used first-line treatment for advanced NSCLC, particularly for the squamous histotype. Necitumumab is nowadays the first targeted agent providing an (statistically significant) additional survival gain to squamous NSCLC patients when combined with first-line chemotherapy at the cost of an increased (although manageable) toxicity, as shown in the SQUIRE trial. Hopefully, improvement in patients’ selection by identifying reliable predictive markers and the combination with new agents may help to maximize the benefit of this targeted treatment, which is currently limited by a not optimal cost–benefit ratio.

Original languageEnglish
Pages (from-to)937-945
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume18
Issue number9
DOIs
Publication statusPublished - Sep 2 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Chemotherapy
Epidermal Growth Factor Receptor
Therapeutics
Cost effectiveness
Platinum
Protein-Tyrosine Kinases
Toxicity
Antibodies, Monoclonal, Humanized
Drug Therapy
Immunoglobulin G
Monoclonal Antibodies
Expert Testimony
Patient Selection
Cost-Benefit Analysis
necitumumab
Survival

Keywords

  • EGFR
  • monoclonal antibody
  • Necitumumab
  • NSCLC
  • squamous

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Necitumumab in the treatment of non-small-cell lung cancer : clinical controversies. / di Noia, Vincenzo; D'Argento, Ettore; Pilotto, Sara; Grizzi, Giulia; Caccese, Mario; Iacovelli, Roberto; Tortora, Giampaolo; Bria, Emilio.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 9, 02.09.2018, p. 937-945.

Research output: Contribution to journalArticle

di Noia, Vincenzo ; D'Argento, Ettore ; Pilotto, Sara ; Grizzi, Giulia ; Caccese, Mario ; Iacovelli, Roberto ; Tortora, Giampaolo ; Bria, Emilio. / Necitumumab in the treatment of non-small-cell lung cancer : clinical controversies. In: Expert Opinion on Biological Therapy. 2018 ; Vol. 18, No. 9. pp. 937-945.
@article{5bce6d594efc4ed3a06911df0c6b1153,
title = "Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies",
abstract = "Introduction: Over the last decade, epidermal growth factor receptor (EGFR) signaling was investigated as a potential target for tyrosine kinase inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Necitumumab is a fully humanized IgG1 monoclonal antibody directed against the binding domain of EGFR, approved in combination with cisplatin–gemcitabine for the first-line treatment of squamous NSCLC. Areas covered: The purpose of this manuscript is to systematically review the state of the art of necitumumab for the treatment of metastatic NSCLC, focusing on predictive factors, cost-effectiveness, and future potential combinations with additional agents. Expert opinion: Despite recent therapeutic advances, platinum-based chemotherapy still represents the most widely used first-line treatment for advanced NSCLC, particularly for the squamous histotype. Necitumumab is nowadays the first targeted agent providing an (statistically significant) additional survival gain to squamous NSCLC patients when combined with first-line chemotherapy at the cost of an increased (although manageable) toxicity, as shown in the SQUIRE trial. Hopefully, improvement in patients’ selection by identifying reliable predictive markers and the combination with new agents may help to maximize the benefit of this targeted treatment, which is currently limited by a not optimal cost–benefit ratio.",
keywords = "EGFR, monoclonal antibody, Necitumumab, NSCLC, squamous",
author = "{di Noia}, Vincenzo and Ettore D'Argento and Sara Pilotto and Giulia Grizzi and Mario Caccese and Roberto Iacovelli and Giampaolo Tortora and Emilio Bria",
year = "2018",
month = "9",
day = "2",
doi = "10.1080/14712598.2018.1508445",
language = "English",
volume = "18",
pages = "937--945",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Necitumumab in the treatment of non-small-cell lung cancer

T2 - clinical controversies

AU - di Noia, Vincenzo

AU - D'Argento, Ettore

AU - Pilotto, Sara

AU - Grizzi, Giulia

AU - Caccese, Mario

AU - Iacovelli, Roberto

AU - Tortora, Giampaolo

AU - Bria, Emilio

PY - 2018/9/2

Y1 - 2018/9/2

N2 - Introduction: Over the last decade, epidermal growth factor receptor (EGFR) signaling was investigated as a potential target for tyrosine kinase inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Necitumumab is a fully humanized IgG1 monoclonal antibody directed against the binding domain of EGFR, approved in combination with cisplatin–gemcitabine for the first-line treatment of squamous NSCLC. Areas covered: The purpose of this manuscript is to systematically review the state of the art of necitumumab for the treatment of metastatic NSCLC, focusing on predictive factors, cost-effectiveness, and future potential combinations with additional agents. Expert opinion: Despite recent therapeutic advances, platinum-based chemotherapy still represents the most widely used first-line treatment for advanced NSCLC, particularly for the squamous histotype. Necitumumab is nowadays the first targeted agent providing an (statistically significant) additional survival gain to squamous NSCLC patients when combined with first-line chemotherapy at the cost of an increased (although manageable) toxicity, as shown in the SQUIRE trial. Hopefully, improvement in patients’ selection by identifying reliable predictive markers and the combination with new agents may help to maximize the benefit of this targeted treatment, which is currently limited by a not optimal cost–benefit ratio.

AB - Introduction: Over the last decade, epidermal growth factor receptor (EGFR) signaling was investigated as a potential target for tyrosine kinase inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Necitumumab is a fully humanized IgG1 monoclonal antibody directed against the binding domain of EGFR, approved in combination with cisplatin–gemcitabine for the first-line treatment of squamous NSCLC. Areas covered: The purpose of this manuscript is to systematically review the state of the art of necitumumab for the treatment of metastatic NSCLC, focusing on predictive factors, cost-effectiveness, and future potential combinations with additional agents. Expert opinion: Despite recent therapeutic advances, platinum-based chemotherapy still represents the most widely used first-line treatment for advanced NSCLC, particularly for the squamous histotype. Necitumumab is nowadays the first targeted agent providing an (statistically significant) additional survival gain to squamous NSCLC patients when combined with first-line chemotherapy at the cost of an increased (although manageable) toxicity, as shown in the SQUIRE trial. Hopefully, improvement in patients’ selection by identifying reliable predictive markers and the combination with new agents may help to maximize the benefit of this targeted treatment, which is currently limited by a not optimal cost–benefit ratio.

KW - EGFR

KW - monoclonal antibody

KW - Necitumumab

KW - NSCLC

KW - squamous

UR - http://www.scopus.com/inward/record.url?scp=85052927247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052927247&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1508445

DO - 10.1080/14712598.2018.1508445

M3 - Article

C2 - 30075697

AN - SCOPUS:85052927247

VL - 18

SP - 937

EP - 945

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -